Cuorips Inc. (4894) AI Stock Analysis

• Market Cap: ¥66.68B
• Dividend Yield: N/A
• Average Volume (3M): 107.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: 1772.85%
• EPS Growth: 16.16%
• Country: JP
• Employees: 59
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -30.15
• Shares Outstanding: 8,268,076
• 10 Day Avg. Volume: 98,200
• 30 Day Avg. Volume: 107,556
• PEG Ratio: 16.56
• Price to Book (P/B): 12.03
• Price to Sales (P/S): 379.55
• P/FCF Ratio: -74.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: ¥7,878.00 ▲(26.45% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is held down primarily by substantial ongoing losses and heavy cash burn despite strong revenue growth, with technicals also weak as the stock trades below key moving averages. Valuation provides limited support given the negative P/E and lack of dividend yield.

Positive Factors

Balance Sheet Strength

Zero reported debt and ~¥5.5b of equity provide durable financial flexibility: lower fixed financing costs, capacity to fund R&D or commercial scaling, and better negotiating leverage for partnerships or equity raises, supporting strategic options over the next several quarters.

Revenue Growth and Gross Margin

Very strong revenue growth combined with roughly 52% gross margin demonstrates the business can generate meaningful incremental gross profit as sales scale. Those unit economics are a durable foundation for margin improvement if operating costs are disciplined and sales mix continues to scale.

Early Commercial Traction

Reported sharp revenue scaling and repeated reporting cadence indicate early market adoption and product-market fit. Sustained commercial traction is a structural positive because it enables predictable revenue growth, customer learning curves, and the potential for operating leverage as scale increases.

Negative Factors

High Cash Burn

Large negative operating (-¥813m) and free cash flow (-¥893m) in 2025 reflect real cash depletion rather than non‑cash charges. This high burn rate reduces runway, forces capital raises or spending cuts, and constrains strategic investments and partnership flexibility over the next 2–6 months.

Persistent Operating and Net Losses

Very large operating and net losses despite revenue growth indicate the company has not yet achieved scalable profitability. Continued negative operating results will pressure cash, require structural cost changes, and increase execution risk around reaching an operational breakeven sustainably.

Negative Returns / Capital Efficiency

ROE of about -11.7% signals that equity capital is being consumed rather than earning returns, which erodes shareholder value over time. Persistent negative returns limit the company's ability to self-finance growth and increase the likelihood of dilutive financing or strategic restructuring.

Cuorips Inc. Business Overview & Revenue Model

Company Description

Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Cuorips Inc. generates revenue through the development and commercialization of regenerative medicine products targeting cardiac diseases. The company makes money by licensing its proprietary technologies and therapies to pharmaceutical and biotechnology companies. Additionally, Cuorips Inc. may receive funding through collaborative research agreements and partnerships with healthcare institutions and academic entities. Revenue streams could also include milestone payments and royalties from successfully developed and marketed therapies. The company's earnings are significantly influenced by its ability to advance its pipeline products through clinical trials and secure regulatory approvals.

Cuorips Inc. Financial Statement Overview

Summary

Despite sharp revenue growth and solid gross margin, results are dominated by very large operating/net losses and deeply negative operating and free cash flow (high cash burn). The debt-free balance sheet and meaningful equity provide financial flexibility, but ongoing losses and negative returns materially weaken the profile.

Income Statement

Revenue has scaled sharply in the latest year (2025 annual revenue up ~404% to ~¥175m), and gross margin remains solid (~52%). However, profitability is very weak: operating losses remain extremely large (EBIT about -¥590m) and net losses deepened to about -¥644m, leaving net margin highly negative. Overall, the company shows early commercial traction but still lacks a clear path to operating breakeven based on the current cost structure.

Balance Sheet

The balance sheet is conservatively levered with zero reported debt and meaningful equity (~¥5.5b) supporting a largely equity-funded profile. That said, returns remain negative (return on equity around -11.7% in 2025), indicating ongoing value dilution risk if losses persist. Overall financial flexibility looks good, but sustained losses continue to pressure long-term capital efficiency.

Cash Flow

Cash generation is weak, with operating cash flow negative and worsening in 2025 (about -¥813m), and free cash flow also deeply negative (about -¥893m), implying a high cash burn profile. Free cash flow is consistently negative relative to net income (free cash flow to net income > 1), suggesting losses are translating into real cash outflows rather than being primarily non-cash. The key strength is consistency of reporting and a lack of debt-related cash burden, but the burn rate remains the central risk.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	260.31M	175.21M	23.10M	38.28M	13.91M	220.00K
Gross Profit	119.12M	91.56M	9.63M	21.01M	10.65M	138.00K
EBITDA	-570.19M	-565.32M	-518.00M	-371.78M	-280.40M	-221.17M
Net Income	-652.25M	-644.34M	-632.18M	-452.08M	-375.34M	-307.83M
Balance Sheet
Total Assets	5.75B	5.74B	6.18B	3.59B	4.04B	4.36B
Cash, Cash Equivalents and Short-Term Investments	4.85B	4.79B	5.58B	2.94B	3.34B	3.54B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	324.59M	211.91M	200.96M	133.79M	149.36M	141.95M
Stockholders Equity	5.42B	5.53B	5.98B	3.45B	3.90B	4.22B
Cash Flow
Free Cash Flow	0.00	-892.81M	-487.01M	-412.18M	-249.45M	-950.97M
Operating Cash Flow	0.00	-812.62M	-451.06M	-401.61M	-220.76M	-282.80M
Investing Cash Flow	0.00	-119.99M	-35.00M	-8.97M	-28.44M	-670.21M
Financing Cash Flow	0.00	145.11M	3.13B	10.69M	48.54M	3.77B

Cuorips Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6230.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Positive. The current price of 6230 is below the 20-day moving average (MA) of 8821.00, below the 50-day MA of 7774.80, and below the 200-day MA of 6786.60, indicating a neutral trend. The MACD of 56.42 indicates Positive momentum. The RSI at 47.11 is Neutral, neither overbought nor oversold. The STOCH value of 9.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4894.

Cuorips Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4978	59 Neutral	¥17.82B	-54.84	―	―	1.24%	-33.41%
7774	54 Neutral	¥32.33B	-70.05	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4593	50 Neutral	¥59.40B	-18.92	―	―	-82.33%	47.73%
7776	49 Neutral	¥14.17B	-11.63	―	―	-42.49%	-2.37%
4894	45 Neutral	¥66.68B	-86.57	―	―	1772.85%	16.16%
4599	43 Neutral	¥19.24B	-10.06	―	―	―	11.34%